KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Tax Provisions: 2013-2024

Historic Tax Provisions for Travere Therapeutics (TVTX) over the last 12 years, with Dec 2024 value amounting to $120,000.

  • Travere Therapeutics' Tax Provisions rose 109.52% to $8,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5,000, marking a year-over-year decrease of 101.92%. This contributed to the annual value of $120,000 for FY2024, which is 46.19% down from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Tax Provisions is $120,000, which was down 46.19% from $223,000 recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Tax Provisions registered a high of $409,000 during FY2021, and its lowest value of -$19.4 million during FY2020.
  • Its 3-year average for Tax Provisions is $218,667, with a median of $223,000 in 2023.
  • Its Tax Provisions has fluctuated over the past 5 years, first tumbled by 92,085.71% in 2020, then soared by 102.11% in 2021.
  • Over the past 5 years, Travere Therapeutics' Tax Provisions (Yearly) stood at -$19.4 million in 2020, then soared by 102.11% to $409,000 in 2021, then dropped by 23.47% to $313,000 in 2022, then fell by 28.75% to $223,000 in 2023, then slumped by 46.19% to $120,000 in 2024.